Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Medicago and GSK partner on COVID-19 vaccine trial  

By Brian Buntz | November 16, 2020

MedicagoThe Canadian biotech firm Medicago (CVE:MDG) is hooking up GlaxoSmithKline (NYSE:GSK) on a study involving 30,000 participants. 

The Quebec City-based Medicago had recently announced promising data concerning its plant-based vaccine candidate. 

Medicago’s vaccine is unique in that it uses virus-like particles that resemble the structure of the novel coronavirus but contain no genetic material from the virus. 

The phase 2/3 trial will investigate the safety and immune response of a combination of two doses of Medicago’s vaccine with GSK’s adjuvant. The two doses will be spaced 21 days apart. 

Medicago had recently announced that the plant-derived vaccine showed promising results in a Phase 1 study, which involved two doses of the vaccine candidate. 

The partially blinded study involved 180 volunteers between the ages of 18 and 55. 

Medicago’s vaccine candidate trails those such as Moderna and Pfizer, whose vaccine candidates promise to have an efficacy rate approaching 95% based on interim analyses of Phase 3 trials. Medicago’s product does have a potential advantage over the latter in terms of storage requirements. While Pfizer’s vaccine candidate must be held at –70° C, Medicago expects its vaccine to be stable at 2° to 8°C. Similarly, Moderna’s vaccine can be stored between 2° to 8°C for 30 days and for as long as six months when held at –20° C. 

Tell Us What You Think! Cancel reply

Related Articles Read More >

OncoSec eyes next steps with its cancer immunotherapy candidate
Pharma researcher charged with theft of trade secrets  
Norway investigating deaths of 23 individuals who received COVID-19 vaccine
Pharma image
Here’s what molecular shape can tell you about pharma innovation

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards